Faraday Pharmaceuticals, Inc. — Form D/A
Faraday Pharmaceuticals, Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2017-02-21. The offering totals $32.8M, of which $32.6M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2017-02-21
- Form: D/A
- Accession: 0001614107-17-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $32.8M
- Amount sold: $32.6M
- Remaining: $173K
- Investors: 11
- Date of first sale: 2014-07-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-221669
Issuer
- Name: Faraday Pharmaceuticals, Inc.
- CIK: 0001614107
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 1616 EASTLAKE AVENUE E., SEATTLE, WA, 98102
- Phone: 206-492-5310
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| Paulina Hill | Director | Cambridge, MA |
| Steven Gillis | Executive Officer | South San Francisco, CA |
| Mark Roth | Executive Officer | Seattle, WA |
| Steven Gillis | Promoter | South San Francisco, CA |
| Steven Gillis | Director | South San Francisco, CA |
| Thomas King | Director | Brooklyn, NY |
| Stephen Hill | Director | Lake Forest, IL |
| Stephen Hill | Executive Officer | Lake Forest, IL |
| Lawrence Gozlan | Director | Fort Collins, CO |
| Robert Nelsen | Director | Seattle, WA |
| Simon Tulloch | Executive Officer | Seattle, WA |
| Brian Blackman | Executive Officer | Seattle, WA |
| Patrick Rock | Executive Officer | Seattle, WA |
| Terrance McGuire | Director | Cambridge, MA |
| Mark Roth | Director | Seattle, WA |
| Mark Roth | Promoter | Seattle, WA |
| Ronald Kierpa | Executive Officer | Seattle, WA |
Other filings by this issuer (4)
More